Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase

Mateusz Rytelewski, Courtney E. Meilleur, Maryam Atef Yekta, Peter A. Szabo, Nitan Garg, Todd Schell, Anthony M. Jevnikar, Shayan Sharif, Bhagirath Singh, S. M.Mansour Haeryfar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme known to suppress antitumor CD8+ T cells (TCD8). The role of IDO in regulation of antiviral TCD8 responses is far less clear. In addition, whether IDO controls both immunodominant and subdominant T CD8 is not fully understood. This is an important question because the dominance status of tumor- and virus-specific TCD8 may determine their significance in protective immunity and in vaccine design. We evaluated the magnitude and breadth of cross-primed TCD8 responses to simian virus 40 (SV40) large T antigen as well as primary and recall TCD8 responses to influenza A virus (IAV) in the absence or presence of IDO. IDOT-/- mice and wild-type mice treated with 1-methyl-D-tryptophan, a pharmacological inhibitor of IDO, exhibited augmented responses to immunodominant epitopes encoded by T antigen and IAV. IDO-mediated suppression of these responses was independent of CD4+CD25+FoxP3+ regulatory T cells, which remained numerically and functionally intact in IDOT-/- mice. Treatment with L-kynurenine failed to inhibit TCD8 responses, indicating that tryptophan metabolites are not responsible for the suppressive effect of IDO in our models. Immunodominant T antigen-specific TCD8 from IDOT-/- mice showed increased Ki- 67 expression, suggesting that they may have acquired a more vigorous proliferative capacity in vivo. In conclusion, IDO suppresses immunodominant TCD8 responses to tumor and viral antigens. Our work also demonstrates that systemic primary and recall TCD8 responses to IAV are controlled by IDO. Inhibition of IDO thus represents an attractive adjuvant strategy in boosting anticancer and antiviral TCD8 targeting highly immunogenic antigens.

Original languageEnglish (US)
Article numbere90439
JournalPloS one
Volume9
Issue number2
DOIs
StatePublished - Feb 28 2014

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
T-cells
Antiviral Agents
T-lymphocytes
T-Lymphocytes
Viruses
Viral Tumor Antigens
Influenza A virus
Tryptophan
tryptophan
antigens
Immunodominant Epitopes
mice
Simian virus 40
indoleamine 2,3-dioxygenase
kynurenine
Kynurenine
Oncogenic Viruses
neoplasms
viral antigens

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Rytelewski, M., Meilleur, C. E., Yekta, M. A., Szabo, P. A., Garg, N., Schell, T., ... Haeryfar, S. M. M. (2014). Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. PloS one, 9(2), [e90439]. https://doi.org/10.1371/journal.pone.0090439
Rytelewski, Mateusz ; Meilleur, Courtney E. ; Yekta, Maryam Atef ; Szabo, Peter A. ; Garg, Nitan ; Schell, Todd ; Jevnikar, Anthony M. ; Sharif, Shayan ; Singh, Bhagirath ; Haeryfar, S. M.Mansour. / Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. In: PloS one. 2014 ; Vol. 9, No. 2.
@article{01a2dd0ff29b4903b0384332b546475b,
title = "Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase",
abstract = "Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme known to suppress antitumor CD8+ T cells (TCD8). The role of IDO in regulation of antiviral TCD8 responses is far less clear. In addition, whether IDO controls both immunodominant and subdominant T CD8 is not fully understood. This is an important question because the dominance status of tumor- and virus-specific TCD8 may determine their significance in protective immunity and in vaccine design. We evaluated the magnitude and breadth of cross-primed TCD8 responses to simian virus 40 (SV40) large T antigen as well as primary and recall TCD8 responses to influenza A virus (IAV) in the absence or presence of IDO. IDOT-/- mice and wild-type mice treated with 1-methyl-D-tryptophan, a pharmacological inhibitor of IDO, exhibited augmented responses to immunodominant epitopes encoded by T antigen and IAV. IDO-mediated suppression of these responses was independent of CD4+CD25+FoxP3+ regulatory T cells, which remained numerically and functionally intact in IDOT-/- mice. Treatment with L-kynurenine failed to inhibit TCD8 responses, indicating that tryptophan metabolites are not responsible for the suppressive effect of IDO in our models. Immunodominant T antigen-specific TCD8 from IDOT-/- mice showed increased Ki- 67 expression, suggesting that they may have acquired a more vigorous proliferative capacity in vivo. In conclusion, IDO suppresses immunodominant TCD8 responses to tumor and viral antigens. Our work also demonstrates that systemic primary and recall TCD8 responses to IAV are controlled by IDO. Inhibition of IDO thus represents an attractive adjuvant strategy in boosting anticancer and antiviral TCD8 targeting highly immunogenic antigens.",
author = "Mateusz Rytelewski and Meilleur, {Courtney E.} and Yekta, {Maryam Atef} and Szabo, {Peter A.} and Nitan Garg and Todd Schell and Jevnikar, {Anthony M.} and Shayan Sharif and Bhagirath Singh and Haeryfar, {S. M.Mansour}",
year = "2014",
month = "2",
day = "28",
doi = "10.1371/journal.pone.0090439",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

Rytelewski, M, Meilleur, CE, Yekta, MA, Szabo, PA, Garg, N, Schell, T, Jevnikar, AM, Sharif, S, Singh, B & Haeryfar, SMM 2014, 'Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase', PloS one, vol. 9, no. 2, e90439. https://doi.org/10.1371/journal.pone.0090439

Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. / Rytelewski, Mateusz; Meilleur, Courtney E.; Yekta, Maryam Atef; Szabo, Peter A.; Garg, Nitan; Schell, Todd; Jevnikar, Anthony M.; Sharif, Shayan; Singh, Bhagirath; Haeryfar, S. M.Mansour.

In: PloS one, Vol. 9, No. 2, e90439, 28.02.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase

AU - Rytelewski, Mateusz

AU - Meilleur, Courtney E.

AU - Yekta, Maryam Atef

AU - Szabo, Peter A.

AU - Garg, Nitan

AU - Schell, Todd

AU - Jevnikar, Anthony M.

AU - Sharif, Shayan

AU - Singh, Bhagirath

AU - Haeryfar, S. M.Mansour

PY - 2014/2/28

Y1 - 2014/2/28

N2 - Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme known to suppress antitumor CD8+ T cells (TCD8). The role of IDO in regulation of antiviral TCD8 responses is far less clear. In addition, whether IDO controls both immunodominant and subdominant T CD8 is not fully understood. This is an important question because the dominance status of tumor- and virus-specific TCD8 may determine their significance in protective immunity and in vaccine design. We evaluated the magnitude and breadth of cross-primed TCD8 responses to simian virus 40 (SV40) large T antigen as well as primary and recall TCD8 responses to influenza A virus (IAV) in the absence or presence of IDO. IDOT-/- mice and wild-type mice treated with 1-methyl-D-tryptophan, a pharmacological inhibitor of IDO, exhibited augmented responses to immunodominant epitopes encoded by T antigen and IAV. IDO-mediated suppression of these responses was independent of CD4+CD25+FoxP3+ regulatory T cells, which remained numerically and functionally intact in IDOT-/- mice. Treatment with L-kynurenine failed to inhibit TCD8 responses, indicating that tryptophan metabolites are not responsible for the suppressive effect of IDO in our models. Immunodominant T antigen-specific TCD8 from IDOT-/- mice showed increased Ki- 67 expression, suggesting that they may have acquired a more vigorous proliferative capacity in vivo. In conclusion, IDO suppresses immunodominant TCD8 responses to tumor and viral antigens. Our work also demonstrates that systemic primary and recall TCD8 responses to IAV are controlled by IDO. Inhibition of IDO thus represents an attractive adjuvant strategy in boosting anticancer and antiviral TCD8 targeting highly immunogenic antigens.

AB - Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-degrading enzyme known to suppress antitumor CD8+ T cells (TCD8). The role of IDO in regulation of antiviral TCD8 responses is far less clear. In addition, whether IDO controls both immunodominant and subdominant T CD8 is not fully understood. This is an important question because the dominance status of tumor- and virus-specific TCD8 may determine their significance in protective immunity and in vaccine design. We evaluated the magnitude and breadth of cross-primed TCD8 responses to simian virus 40 (SV40) large T antigen as well as primary and recall TCD8 responses to influenza A virus (IAV) in the absence or presence of IDO. IDOT-/- mice and wild-type mice treated with 1-methyl-D-tryptophan, a pharmacological inhibitor of IDO, exhibited augmented responses to immunodominant epitopes encoded by T antigen and IAV. IDO-mediated suppression of these responses was independent of CD4+CD25+FoxP3+ regulatory T cells, which remained numerically and functionally intact in IDOT-/- mice. Treatment with L-kynurenine failed to inhibit TCD8 responses, indicating that tryptophan metabolites are not responsible for the suppressive effect of IDO in our models. Immunodominant T antigen-specific TCD8 from IDOT-/- mice showed increased Ki- 67 expression, suggesting that they may have acquired a more vigorous proliferative capacity in vivo. In conclusion, IDO suppresses immunodominant TCD8 responses to tumor and viral antigens. Our work also demonstrates that systemic primary and recall TCD8 responses to IAV are controlled by IDO. Inhibition of IDO thus represents an attractive adjuvant strategy in boosting anticancer and antiviral TCD8 targeting highly immunogenic antigens.

UR - http://www.scopus.com/inward/record.url?scp=84896522334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896522334&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0090439

DO - 10.1371/journal.pone.0090439

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e90439

ER -